STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review

More than 90 fusion partners of ALK have been reported in NSCLC patients.
Striatin gene (STRN)-ALK fusion has rarely been reported. Case study of NSCLC patient harboring an STRN-ALK fusion and exhibiting an excellent response to alectinib treatment. READ ARTICLE

OncoTargets and Therapy DOI: 10.2147/OTT.S282933

Authors: Su C, Jiang Y, Jiang W, Wang H, Liu S, Shao Y, Zhao W, Ning R, Yu Q.

Case StudyKirk SmithNovember 6, 2020lung adenocarcinoma, STRN-ALK fusion, ctDNA, alectinib, targeted NGS